May 30

Pharmaphorum Podcast: Move over CAR-T – the Potential of NK Cells in Cell Therapy

[excerpt] The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren’t the only option for cell therapy. Promising work is being done with natural killer, or NK cells, a different kind of immune system cell that could work even better in some ways.

On this pharmaphorum podcast, Dr. Fred Aslan, Artiva’s CEO talks with host Jonah Comstock about the potential of NK cells as an allogeneic cell therapy approach in autoimmune disease and the importance of a robust manufacturing process.

Find episode 126 (dated May 30, 2024) on iTunesSpotify, and Stitcher or on pharmaphorum’s website, which has a podcast player or the option to download the episode.

Recent Posts

Pharmaphorum Podcast: Move over CAR-T – the Potential of NK Cells in Cell Therapy

[excerpt] The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren’t the only option for cell therapy. Promising work is being done with natural killer, or NK cells, a different kind of immune system cell that could work even better in some ways....

Artiva Biotherapeutics Readies for the Next Phase of Growth with the Appointment of Neha Krishnamohan as CFO and EVP, Corporate Development and Promotion of Jennifer Bush to Chief Operating Officer

Neha Krishnamohan brings extensive experience across strategic growth, business development, M&A and financing Jennifer Bush, Esq., who brings 14 years of executive leadership, has been promoted to Chief Operating Officer  SAN DIEGO, April 24, 2024 — Artiva Biotherapeutics, Inc., a clinical-stage company whose mission is to deliver broadly accessible, off-the-shelf natural killer (NK) cell-based therapies...

Cell & Gene: NK Cell Therapies – How Artiva Biotherapeutics Leverages Its “Manufacturing First” Approach

Chris Horan, chief technical operations officer, Artiva Biotherapeutics discusses with Cell & Gene natural killer (NK) cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK. He answers the following questions: Why do NK cell therapies hold promise in treating autoimmune disease? What is the biggest technical/scientific challenge of developing NK-based therapies, and what...